Search results
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This...
Motley Fool· 6 months agoWeight-loss drugs present an enormous opportunity in the healthcare market. Wegovy and Mounjaro are...
Lilly rides wave of weight-loss drug demand, working to expand capacity
Reuters via AOL· 4 months agoEli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for...
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Motley Fool via Yahoo Finance· 3 months agoEli Lilly and Novo Nordisk have been among the hottest healthcare stocks to own over the past few...
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
InvestorPlace via Yahoo Finance· 2 weeks agoInvestors are well aware of the explosive growth potential in weight loss drug stocks. That growth...
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
InvestorPlace via Yahoo Finance· 1 month agoInvestors continue to search for the next big weight loss drug stocks following the success of Eli...
As Zepbound shortage grows, Eli Lilly says there's no immediate end in sight
NBC Universal via AOL· 1 month agoZepbound drugmaker Eli Lilly is working to increase its weight loss drug supply. But some steps to...
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Benzinga via Yahoo Finance· 1 month agoThe GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a...
New drugs and surgery can deliver major weight loss. But they come at a cost.
USA TODAY via Yahoo News· 2 years agoEditor’s note: Part 5 of a six-part USA TODAY series examining America’s obesity epidemic. For two...
IBD Stock Of The Day Eli Lilly Jumps Early Entry As Viking Charges Obesity Space
Investor's Business Daily· 2 months agoEli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are forming a flat base as competition...
Novo, Lilly buoyed by fast-growing GLP-1 drug sales
BioPharma Dive via Yahoo Finance· 7 months agoNovo Nordisk and Eli Lilly on Thursday reported strong sales growth for their rival GLP-1 metabolic disease drugs, setting up a 2024 showdown as the...